Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

Alcon

Status and phase: Completed; Phase 3

Conditions: Cataract

Treatments: Drug: Nepafenac Ophthalmic Suspension, 0.1%

Study type: Interventional

Funder types: Industry

Identifiers

NCT00333255

C-04-41

Details and patient eligibility

About

The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.

Enrollment: 267 patients

Sex: All

Ages: 10+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• planned cataract extraction with posterior chamber intraocular lens implantation

Exclusion criteria

• Under 10

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind